# Gerhard Bogner

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gerhard-bogner/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,443 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 16 |
| i10-index | 22 |
| Last Known Institution | Universitätsklinik für Frauenheilkunde und Geburtshilfe |
| OpenAlex ID | https://openalex.org/A5060960328 |
| ORCID iD | 0000-0002-4495-1209 |
| Works | 144 |

## Researcher papers

- [Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial](https://scholariq.org/papers/olaparib-plus-bevacizumab-first-line-maintenance-in-ovarian-cancer-final-overall/)
- [Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective](https://scholariq.org/papers/decrease-in-gynecological-cancer-diagnoses-during-the-covid-19-pandemic-an/)
- [The surgical safety checklist and patient outcomes after surgery: a prospective observational cohort study, systematic review and meta-analysis](https://scholariq.org/papers/the-surgical-safety-checklist-and-patient-outcomes-after-surgery-a-prospective/)
- [Combined Transvaginal B-Mode and Color Doppler Sonography for Differential Diagnosis of Ovarian Tumors: Results of a Multivariate Logistic Regression Analysis](https://scholariq.org/papers/combined-transvaginal-b-mode-and-color-doppler-sonography-for-differential/)
- [Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial](https://scholariq.org/papers/efficacy-of-maintenance-olaparib-plus-bevacizumab-according-to-clinical-risk-in/)
- [Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/trebananib-or-placebo-plus-carboplatin-and-paclitaxel-as-first-line-treatment/)
- [Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial](https://scholariq.org/papers/topical-imiquimod-versus-surgery-for-vulvar-intraepithelial-neoplasia-a/)
- [Breech delivery in the all fours position: a prospective observational comparative study with classic assistance](https://scholariq.org/papers/breech-delivery-in-the-all-fours-position-a-prospective-observational/)
- [First trimester three-dimensional ultrasound volumetry of the gestational sac](https://scholariq.org/papers/first-trimester-three-dimensional-ultrasound-volumetry-of-the-gestational-sac/)
- [LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)](https://scholariq.org/papers/lba29-final-overall-survival-os-results-from-the-phase-iii-paola-1-engot-ov25/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Maternal and Perinatal Health Interventions](https://scholariq.org/topics/maternal-and-perinatal-health-interventions/)
- [Pelvic floor disorders treatments](https://scholariq.org/topics/pelvic-floor-disorders-treatments/)

## Researcher university

- [Universitätsklinik für Frauenheilkunde und Geburtshilfe](https://scholariq.org/institutions/universitatsklinik-fur-frauenheilkunde-und-geburtshilfe/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.